The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib

C. Miething, S. Feihl, C. Mugler, R. Grundler, N. von Bubnoff, F. Lordick, C. Peschel, Justus Duyster

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib'. Together they form a unique fingerprint.

Keyphrases

Neuroscience

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science